Compare REGN & MO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | MO |
|---|---|---|
| Founded | 1988 | 1822 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 98.6B |
| IPO Year | 1995 | 1994 |
| Metric | REGN | MO |
|---|---|---|
| Price | $759.58 | $66.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 9 |
| Target Price | ★ $815.04 | $62.75 |
| AVG Volume (30 Days) | 638.2K | ★ 7.8M |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | 0.49% | ★ 6.33% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | 4.12 |
| Revenue | $5,872,227,000.00 | ★ $23,279,000,000.00 |
| Revenue This Year | $11.69 | $3.66 |
| Revenue Next Year | $10.12 | $0.46 |
| P/E Ratio | $18.41 | ★ $16.33 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $476.49 | $53.41 |
| 52 Week High | $821.11 | $70.51 |
| Indicator | REGN | MO |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 51.74 |
| Support Level | $740.39 | $65.62 |
| Resistance Level | $786.67 | $67.12 |
| Average True Range (ATR) | 21.54 | 1.27 |
| MACD | -2.98 | -0.42 |
| Stochastic Oscillator | 18.91 | 14.47 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Altria comprises Philip Morris USA, US Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 42% annual share in 2024. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev and a 41% stake in cannabis manufacturer Cronos. It also acquired vaping company Njoy Holdings in 2023 and operates a joint venture with Japan Tobacco in the heated tobacco category for the US.